Dr. Veerapol Khemarangsan, Chief Executive Officer of Medeze Group Public Company Limited (SET: MEDEZE), stated that the company aims for 25% growth in its 2026 operations, marking it as a year of tangible strategic elevation for MEDEZE. The company seeks to leverage its strengths in the Biobank field to become a clear leader in the Biopharma and Advanced Therapy industries, while building a comprehensive health ecosystem to support the growth of the health economy both domestically and regionally.
In terms of Advanced Therapy Medicinal Products (ATMPs) development, the company is focused on further innovation for treating degenerative diseases. The initial targets include products for osteoarthritis and skin degeneration, with plans to register two product groups each year to meet the need for treatment, rehabilitation, and preventive healthcare amid an aging population.
Simultaneously, MEDEZE is expanding internationally via a franchise model and has already signed an agreement to operate in Mongolia, while preparations are underway to begin operations in the Philippines in 2026. The company also aims to add an average of one new international agreement per year to systematically build a regional health ecosystem network.
For infrastructure, MEDEZE has entered into a strategic partnership with the Government Pharmaceutical Organization (GPO) and partners to establish a joint venture for domestic production of culture media, aiming to reduce dependency on imported medical raw materials.
The subsidiary, which will operate under MEDEZE, is expected to commence commercial operations in 1Q26. This move will strengthen the medical biotechnology supply chain and lay a foundation for Thailand and Southeast Asia to become a future base for ATMP manufacturing.
Additionally, MEDEZE emphasizes raising operational standards to international levels, with planned investment in Robotics and Automation technologies for laboratories, alongside upgrading all laboratories to Good Manufacturing Practice (GMP) standards to enhance accuracy and support long-term business growth.
Moreover, MEDEZE gives importance to value-added programs for listed companies (JUMP+), an initiative supported by the Stock Exchange of Thailand (SET) to elevate organizational capabilities in every dimension, from business strategy, finance, and corporate governance to sustainable growth.
Participation in JUMP+ allows MEDEZE to systematically review and develop business plans, including organizational potential analysis, business model design, action plan formulation, and linking economic outcomes with long-term sustainability.
Looking ahead, the company aims to extend its health ecosystem through collaboration with hospitals, clinics, research institutes, and partners both domestically and abroad. It also prioritizes sustainability and long-term growth by operating under good governance, risk management, and systematic ESG principles, as well as creating shared value for the public health system, economy, and society as a whole.
